North America Life Science Market Trends for 2026

The North America life science market size is calculated at US$ 39.70 billion in 2025, grew to US$ 44.49 billion in 2026, and is projected to reach around US$ 124.18 billion by 2035. The market is expanding at a CAGR of 12.08% between 2026 and 2035.

The growing diseases are driving the R&D activities in North America, which is enhancing the life sciences sector, enhancing the development of advanced therapies, genomics, and personalized medicines. At the same time, the growing funding and investments are increasing the adoption of advanced technologies like AI, which are being used to accelerate drug development, clinical trials, and to develop new models. Additionally, the companies are also developing, investing, and launching new drug products as well as platforms, which are promoting the market growth.

Key Takeaways

• North America life science sector pushed the market to USD 44.49 billion by 2026.
• Long-term projections show USD 124.18 billion valuation by 2035.
• Growth is expected at a steady CAGR of 12.08% in between 2026 to 2035.
• The global life sciences market is set to grow from US$ 98.63 billion in 2025 to US$ 269.56 billion by 2034, at a CAGR of 11.82%.
• The U.S held approximately an 88% share in the global North America life science market in 2025.
• By product type, the instruments segment held an approximate 50% share in the market in 2025.
• By product type, the software & services segment is expected to be the fastest growing during the forecast period.
• By technology type, the genomics segment held approximately a 45% share in the market in 2025.
• By technology type, the AI & digital platforms in the life sciences segment are expected to be the fastest growing during the forecast period.
• By application type, the drug discovery & development segment held approximately a 42% share in the North America life science market in 2025.
• By application type, the personalized medicine segment is expected to be the fastest-growing during the forecast period.
• By end user, the pharmaceutical & biotechnology companies segment held an approximate 44% share in the global market in 2025.
• By end user, the hospitals & clinical research laboratories segment is expected to be the fastest growing during the forecast period.

What does the North America Life Science Encompass?

The North America life science market is driven by high investments in research and development, strong government support, and technological advancements. The North American Life Science encompasses the research, development, manufacturing, and commercialization of biopharmaceuticals, biotechnology products, diagnostics, laboratory tools, and advanced therapeutics across the United States and Canada, including instruments, reagents, consumables, software, and services used in drug discovery, clinical diagnostics, genomics, proteomics, molecular biology, and personalized medicine.

Growth is driven by robust healthcare and R&D spending, advanced biomanufacturing infrastructure, adoption of next-generation sequencing, AI-driven analytics, and supportive regulatory frameworks. The region benefits from a dense network of pharmaceutical and biotechnology companies, leading academic institutes, and established CRO/CDMO infrastructure, and the challenges include high innovation costs, competitive saturation, and complex reimbursement, but opportunities exist in precision medicine, advanced diagnostics, AI-based platforms, and cell and gene therapy adoption.

North America Life Science Sector Powers the Next Wave of Healthcare Innovation

Life science encompasses the study and application of biology, biotechnology, pharmaceuticals, medical devices, diagnostics, and related technologies to improve human health, develop innovative therapies, and advance scientific research, increasing demand for precision medicine and growing clinical trial activities across the region. A key trend is the rapid adoption of artificial intelligence, laboratory automation, and advanced data analytics to accelerate research and drug development. Technological advancements in genomics, gene editing, cell and gene therapies, single-cell sequencing, and digital laboratory platforms are transforming healthcare innovation. Future opportunities lie in personalized medicine, synthetic biology, regenerative medicine, AI-driven drug discovery, and sustainable biomanufacturing, supported by strong research infrastructure, favorable funding, and strategic collaborations between academia, biotechnology companies, and pharmaceutical organizations.

Key Internal and External Forces Shaping the North America Life Science Market

The North America life science market is influenced by a combination of internal capabilities and external industry dynamics. Internally, strong research infrastructure, advanced biotechnology platforms, skilled scientific talent, robust R&D investments, and the adoption of AI, automation, and genomics technologies accelerate innovation and product development. However, high research costs, lengthy development timelines, and complex regulatory compliance remain key challenges. Externally, the market is driven by increasing demand for biologics, precision medicine, and advanced therapeutics, growing healthcare expenditure, favourable government funding, and strategic collaborations among academia and industry. At the same time, evolving regulatory policies, supply chain disruptions, intellectual property concerns, and global competition continue to influence market growth and long-term innovation.

North America Life Science Market Outlook

• Industry Growth Overview: The life sciences industries in North America are expected to show strong growth due to growing investment in R&D and advanced technologies such as gene editing and AI. The growth in the demand for personalized medicines, sophisticated analytical tools, and biopharmaceuticals is driving this growth.
• Sustainability Trends: The growing adoption of green chemistry, implementation of circular economy practices, and minimizing energy use are promoting the sustainability trends in the life science sector. Moreover, the growing investment in the greener process and supply chain improvements is contributing to the same.
• Startup Ecosystem: The startup ecosystem is focusing on developing advanced treatments for genetic diseases and cancer, utilizing AI, gene editing, and cell and gene therapies. Moreover, they are also focusing on merging technology with biotechnology to develop digital health solutions, accelerating R&D and patient care with the use of lab automation or wearable devices.

AI Technological Shifts in the North America Life Science Market

The use of AI in the life sciences is increasing, as it provides various platforms enhancing drug discovery and development, clinical trials, diagnostics, etc. It is also being used in the development of personalized medicines with the use of multi-omics or genomics data. Additionally, AI virtual cell models are also being developed to test biological hypotheses without traditional lab experiments.

For instance,

• In August 2025, to transform the development in cell biology, an AI Virtual Cell Model was introduced with the support of the Chan Zuckerberg Initiative (CZI). With the use of this platform, biomedical research and drug discovery will be accelerated, and the costs of biological experiments will be reduced.

What are the North America Life Science Market Trends?

Growing investments: Due to growing demand for personalized treatment and growing diseases, there is a rise in investment and funding in the life sciences sector of North America. The companies are focusing on developing new platforms to enhance drug development as well as to develop novel diagnostic techniques. Moreover, to support these advancements, the companies are also introducing new initiatives.

For instance,

• In October 2025, the nation’s first multi-state genomic newborn screening initiative, that is BEACONS (Building Evidence and Collaboration for Genomics in Nationwide Newborn Screening), was launched by GeneDx. The whole genome sequencing will be integrated into the existing state newborn screening systems by BEACONS, which is supported by $14.4 million funding provided by the National Institutes of Health (NIH) Common Fund Venture Program.
• In June 2025, the commercialization of the first embryo screening test using whole genome and transcriptome sequencing, developed by Juniper Genomics, a Canada-based company, announced the launch of $4.6 million in seed funding. For IVF genetic testing by analyzing millions of genetic markers, the company is aiming to develop a new clinical standard.

Table: Latest Diagnostics Platforms Launched Across North America

Executive Summary Table

Segmental Insights

By Product Type

Which Product Type Segment Held the Dominating Share of the North America Life Science Market in 2025?

By product type, the instruments segment held the dominating share of approximately 50% in the market in 2025, driven by growing R&D activities. At the same time, the growth in R&D investment also increased the use of advanced instruments in the industries. Similarly, the growth in clinical trials also contributed to the same. Moreover, growing technological advancements have also increased their demand.

By product type, the software & services segment is expected to show the highest growth during the forecast period. The growing use of genomics is increasing its use for the analysis and interpretation of vast amounts of data. Moreover, they are being used in decentralized clinical trials. Additionally, their affordability, scalability, and regulatory compliance are increasing their use.

By Technology

How Genomics Segment Dominated the North America Life Science Market in 2025?

By technology type, the genomics segment led the market with approximately a 45% share in 2025, due to growing demand for personalized medicines. At the same time, the growing cancer research has also increased its use for the detection of mutations. Furthermore, they were also used to identify the drug targets and biomarkers.

By technology type, the AI & digital platforms in the life sciences segment are expected to show the fastest growth rate during the forecast period. Their use is increasing as these platforms help in accelerating drug discovery and development. They also streamline the analysis, clinical trials, as well as promote real-time monitoring.

By Application

What Made Drug Discovery & Development the Dominant Segment in the North America Life Science Market in 2025?

By application type, the drug discovery & development segment held the largest share of approximately 42% in the market in 2025, due to growth in drug and therapy development. The growing chronic diseases also promoted their development. Moreover, the growth in the use of genomics and AI platforms has also accelerated their R&D.

By application type, the personalized medicine segment is expected to show the highest growth during the forecast period. The growing demand for targeted therapies is increasing the development of personalized medicines. Additionally, the growing awareness is increasing the use due to its reduced side effects. They are also being used in the treatment of rare diseases and cancer.

By End User

Why Pharmaceutical & Biotechnology Companies Segment Dominated the North America Life Science Market?

By end user, the pharmaceutical & biotechnology companies segment led the global market with approximately 44% share in 2025, driven by the growing R&D. These companies also contributed to the increased development of precision medicine and biologics. Additionally, they also utilized advanced technologies, which accelerated the development of personalized medicines.

By end user, the hospitals & clinical research laboratories segment is expected to show the fastest growth rate during the forecast period. These laboratories are developing various diagnostic techniques along with precision and personalized medicine. Moreover, the growing diseases is increasing the use of these diagnostic platforms, where the use of advanced technologies has increased their accuracy.

Regional Insights

Robust R&D Ecosystem Drives North America

The North America life science market is expanding due to the presence of a robust R&D ecosystem. The life science companies are also investing in the development of innovative therapies like cell and gene therapies. Moreover, the growing R&D supported by the investments and funding from companies and the government also promoted their development. Additionally, they are also focusing on next-generation sequencing and genomics, which contributed to the market growth.

Growth in the R&D Investments Boosts the U.S.

The U.S. held the major share in the North America life science market with 88% in 2025, due to growth in the R&D investments. This, in turn, increased drug discovery and development and technological developments. The growing startup ecosystems also contribute to the increased development of personalized medicine and diagnostics. Additionally, there is a growth in the adoption of AI technologies, which has accelerated the clinical trials and enhanced the market growth.

Country-level analysis

In September 2025, a new biopharmaceutical manufacturing facility was opened by FUJIFILM Biotechnologies in Holly Springs, as a part of a multi-billion-dollar investment in the life sciences sector in the state. The facility is considered to be the largest cell culture biopharmaceutical CDMO facility in North America.

Global Life Science Market Growth

The global life sciences market is valued at US$ 88.2 billion in 2024, rising to US$ 98.63 billion in 2025, and is expected to reach approximately US$ 269.56 billion by 2034. This growth reflects a compound annual growth rate (CAGR) of 11.82% from 2025 to 2034.

North America Life Science Market Value Chain Analysis

R&D

To develop novel treatments for chronic diseases and cancer using technologies such as gene editing and AI is the focus of the North America life science R&D.

Key Players: AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co., Gilead Sciences, Amgen Inc.

Clinical Trials and Regulatory Approvals

The clinical trial and regulatory approval of North America life sciences involve a multiphase process, ensuring the quality, safety, and efficacy of the new drugs and medical devices.

Key Players: AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co., Gilead Sciences, Pfizer Inc., Amgen Inc., Moderna, Inc.

Patient Support and Services

The patient support and services of North America life science companies include management of treatment costs through financial assistance, educational resources to enhance health literacy, and help people access medication.

Key Players: AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co., Gilead Sciences, Pfizer Inc., Amgen Inc., Moderna, Inc.

Top vendors and Their Offerings

• Pfizer Inc.: It is a biopharmaceutical company that is involved in developing innovative solutions to enhance patients' lives. Moreover, they develop drug products for diseases such as autoimmune diseases, blood diseases, cancer, etc.
• Johnson & Johnson (Janssen): It contributes to the development of products in the main 3 sectors, namely pharmaceuticals, medical devices and diagnostics, and consumer health products. Additionally, there are innovative medicines being developed for oncology, immunology, neuroscience, and cardiopulmonary.
• Merck & Co. (MSD): It is a research-intensive biopharmaceutical company. They develop medicines, biologic therapies, vaccines, and animal health products for diseases like cancer, infectious diseases, immunology, etc.
• AbbVie Inc.: It is a pharmaceutical company that provides innovative solutions for cancer, eye care, immunology, and many other conditions. Moreover, they are focusing on personalized medicine, genomics, therapeutic modalities, etc.
• Amgen Inc.: The company combines technology and biotechnology to combat various diseases. It discovers, develops, manufactures, and delivers various innovative solutions targeting heart disease, cancer, rare diseases, osteoporosis, and inflammatory diseases.

Which are the Top Companies in the North America Life Science Market?

• Gilead Sciences
• Moderna, Inc.
• Biogen Inc.
• Regeneron Pharmaceuticals
• Bristol Myers Squibb (BMS)
• Eli Lilly and Company
• Roche (North American operations)
• Novartis (regional presence)
• Thermo Fisher Scientific
• Danaher Corporation (Cytiva, Beckman Coulter)
• Illumina, Inc.
• Agilent Technologies
• Charles River Laboratories
• Lonza (North American facilities)
• Catalent, Inc.

SWOT Analysis

Strengths

• Strong biotechnology and pharmaceutical research ecosystem.
• Advanced healthcare infrastructure and world-class research institutions.
• High investments in R&D from government and private organisations.
• Rapid adoption of AI, genomics, and precision medicine technologies.

Weaknesses

• High research, development, and manufacturing costs.
• Stringent regulatory approval processes.
• Skilled workforce shortages in specialised life science fields.
• Complex reimbursement and pricing challenges.

Opportunities

• Growing demand for cell and gene therapies and personalised medicine.
• Expansion of digital health, laboratory automation, and AI-driven drug discovery.
• Increasing clinical trial activities and biopharmaceutical outsourcing.
• Rising investments in regenerative medicine and synthetic biology.

Threats

•    Regulatory changes and evolving compliance requirements.
•    Supply chain disruptions affecting laboratory and manufacturing operations.
•    Intense competition from emerging global life science hubs.
•    Cybersecurity risks and intellectual property protection challenges

Latest Announcements By Industry Leaders

• In July 2026, "Our collaboration with AstraZeneca highlights how integrated large-scale clinico-genomic data is becoming a foundational resource in advancing biomedical research and therapeutic development," "By combining comprehensive genomic data with rich longitudinal clinical information, we can help accelerate research, generate deeper insights into disease, and advance the development of more targeted medicines”, said James Lu, M.D., Ph.D., CEO and co-founder of Helix.

What are the Recent Developments in the North America Life Science Market?

• In October 2025, breakthrough clinical achievements in precision medicine and significant U.S. market expansion were announced by Gene Matrix Inc. Moreover, the early cancer detection with advanced genomic testing, adverse drug reactions prevention, and mental health treatments optimization is being enhanced by the GeneMatrixAl platform of the company.
• In June 2025, the expanded PanOmiQ™ platform was introduced by BioAro Inc. at the 2025 BIO International Convention held in Boston. The platform has introduced a major update that is PanOmiQ™ Research, which is a powerful, AI-integrated multi-omics and drug discovery solution.

Segments Covered in the Report

By Product Type

• Instruments
  • Chromatography Instruments
  • Spectroscopy Instruments
  • Microscopy Instruments
  • PCR & qPCR Instruments
  • Sequencers & Genomic Analysis Instruments
  • Lab Automation & Robotics
  • Microplate Readers
  • Incubators & Ovens
  • Centrifuges
  • Other Instruments
• Reagents & Consumables
  • Assay Kits
  • Enzymes & Buffers
  • Culture Media & Supplements
  • Plasticware & Glassware
  • Antibodies & Proteins
  • Nucleic Acids & Oligonucleotides
  • Other Consumables
• Software & Services
  • Laboratory Information Management Systems (LIMS)
  • Data Analytics & Bioinformatics Software
  • Consulting Services
  • Training & Support Services

By Technology

• Genomics
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
  • PCR & qPCR
  • Microarrays
• Proteomics
  • Mass Spectrometry
  • Protein Microarrays
  • 2D Gel Electrophoresis
• Cell Biology & Molecular Biology
  • Flow Cytometry
  • CRISPR & Gene Editing
  • Cell Culture & Assays
  • Immunoassays
• Drug Discovery & Development
  • High-Throughput Screening
  • Combinatorial Chemistry
  • Bioassays & Target Validation
• Laboratory Automation & Robotics
  • Liquid Handling Systems
  • Automated Plate Readers
  • Robotic Sample Management
  • AI & digital platforms in the life sciences

By Application

• Drug Discovery & Development
• Diagnostics & Clinical Testing
• Genomics & Proteomics Research
• Molecular & Cell Biology Research
• Personalized Medicine
• Agriculture & Food Testing
• Environmental & Forensic Testing

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Hospitals & Clinical Research Laboratories
• Government & Regulatory Organizations
• Diagnostic Laboratories

By Country

• United States
• Canada
• Mexico
• Rest of North America